Cargando…

Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro

Infusion reactions (IRs) are common immune-mediated side effects in patients treated with a variety of drug products, including, but not limited to, nanotechnology formulations. The mechanism of IRs is not fully understood. One of the best studied mechanisms of IRs to nanomedicines is the complement...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neun, Barry W., Barenholz, Yechezkel, Szebeni, Janos, Dobrovolskaia, Marina A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6100003/ https://www.ncbi.nlm.nih.gov/pubmed/30002298 http://dx.doi.org/10.3390/molecules23071700

Ejemplares similares

Anticoagulants Influence the Performance of In Vitro Assays Intended for Characterization of Nanotechnology-Based Formulations
por: Cedrone, Edward, et al.
Publicado: (2017)

Roadmap and strategy for overcoming infusion reactions to nanomedicines
por: Szebeni, Janos, et al.
Publicado: (2018)

Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance
por: Wei, Xiaohui, et al.
Publicado: (2018)

Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
por: Nordström, Rickard, et al.
Publicado: (2021)

Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice
por: Őrfi, Erik, et al.
Publicado: (2019)

Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization
por: Mészáros, Tamás, et al.
Publicado: (2018)

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG
por: Kozma, Gergely Tibor, et al.
Publicado: (2023)

Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine)
por: Bavli, Yaelle, et al.
Publicado: (2023)

Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil
por: Banciu, Manuela, et al.
Publicado: (2008)

Multimodality Imaging of Tumor Response to Doxil
por: Zhang, Fan, et al.
Publicado: (2011)

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA–Lipid Complexes
por: Szebeni, János, et al.
Publicado: (2023)

PEGylated Liposomal Methyl Prednisolone Succinate does not Induce Infusion Reactions in Patients: A Correlation Between in Vitro Immunological and in Vivo Clinical Studies
por: Bavli, Yaelle, et al.
Publicado: (2020)

Infusion Reactions Associated with the Medical Application of Monoclonal Antibodies: The Role of Complement Activation and Possibility of Inhibition by Factor H
por: Fülöp, Tamás, et al.
Publicado: (2018)

Nanoparticle Effects on Human Platelets in Vitro: A Comparison between PAMAM and Triazine Dendrimers
por: Enciso, Alan E., et al.
Publicado: (2016)

Optimization of post-insertion method to conjugate Doxil with anti-CD133 monoclonal antibodies: Investigating the specific binding and cytotoxicity to colorectal cancer cells in vitro
por: Dadashi Noshahr, Karim, et al.
Publicado: (2020)

Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity
por: Helke, Kristi L., et al.
Publicado: (2022)

An In Vitro Assessment of Immunostimulatory Responses to Ten Model Innate Immune Response Modulating Impurities (IIRMIs) and Peptide Drug Product, Teriparatide
por: Holley, Claire K., et al.
Publicado: (2021)

Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells
por: Schubert, Mollie S., et al.
Publicado: (2018)

Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi, Reza, et al.
Publicado: (2020)

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm
por: Kozma, Gergely Tibor, et al.
Publicado: (2021)

Detection of Beta-Glucan Contamination in Nanotechnology-Based Formulations
por: Neun, Barry W., et al.
Publicado: (2020)

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
por: Rios-Doria, Jonathan, et al.
Publicado: (2015)

Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors
por: You, Shaojin, et al.
Publicado: (2010)

Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)
por: Tsukioka, Yoshihisa, et al.
Publicado: (2002)

Ratiometric delivery of doxorubicin and berberine by liposome enables superior therapeutic index than Doxil(Ⓡ)
por: Zhang, Ruoshi, et al.
Publicado: (2020)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

Hyperbaric Oxygen Potentiates Doxil Antitumor Efficacy by Promoting Tumor Penetration and Sensitizing Cancer Cells
por: Wu, Xian, et al.
Publicado: (2018)

Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers
por: Huckaby, Justin T., et al.
Publicado: (2020)

Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil(®)) to Tumour Cells Using a Novel TIMP3 Peptide
por: Aldughaim, Mohammed S., et al.
Publicado: (2020)

Role of complement activation in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis
por: Kojima, Tadasu, et al.
Publicado: (2022)

A porcine model of hemodialyzer reactions: roles of complement activation and rinsing back of extracorporeal blood
por: Pethő, Ákos, et al.
Publicado: (2021)

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor
por: Dézsi, László, et al.
Publicado: (2022)

Therapeutic Efficacy of Combining PEGylated Liposomal Doxorubicin and Radiofrequency (RF) Ablation: Comparison between Slow-Drug-Releasing, Non-Thermosensitive and Fast-Drug-Releasing, Thermosensitive Nano-Liposomes
por: Andriyanov, Alexander V., et al.
Publicado: (2014)

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model
por: Bavli, Yaelle, et al.
Publicado: (2021)

A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer
por: Gibbs, D D, et al.
Publicado: (2002)

Complement Activation-Related Pathophysiological Changes in Anesthetized Rats: Activator-Dependent Variations of Symptoms and Mediators of Pseudoallergy
por: Dézsi, László, et al.
Publicado: (2019)

Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (Doxil(®)) in C26 Tumor-Bearing Immunocompetent Mice
por: Takayama, Takuma, et al.
Publicado: (2020)

Multistep, effective drug distribution within solid tumors
por: Shemi, Amotz, et al.
Publicado: (2015)

Immunorthodontics: in vivo gene expression of orthodontic tooth movement
por: Klein, Yehuda, et al.
Publicado: (2020)

PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors
por: Grabarnick (Portnoy), Emma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_agnih9s6jb3d820b0gltl77fg9